GMP-Grade Human iPSC Lines and Matched Research-Grade Lines
Watch this webinar to learn how LineaBio’s GMP-grade manufacturing framework, combined with º£½ÇÆƽâ°æ’s rigorous quality control for matched research-grade cell lines, can support your PSC-derived cell therapy development. You may also sign up to be notified when these products launch.
Reliable and traceable starting materials, such as high-quality human induced pluripotent stem cell (hiPSC) lines, are essential for enabling reproducible PSC-derived cell therapy development. However, many research-grade materials are generated under donor, consent, or process constraints that prevent rederivation under GMP conditions, which limits their suitability for clinical translation.
To address these challenges, LineaBio has introduced the GMP-grade hiPSC lines, Linea 1 and Linea 2, produced under defined, quality-controlled processes. In partnership with º£½ÇÆƽâ°æ Technologies, matched research-grade equivalents are derived from the same source material and qualified to meet or exceed ISSCR standards. Selecting matched starting materials enables smoother advancement through development stages and lowers the likelihood of requiring process redesign at later phases.
Watch this webinar to learn how LineaBio’s GMP-grade manufacturing framework, combined with º£½ÇÆƽâ°æ’s rigorous quality control for matched research-grade cell lines, can support your PSC-derived cell therapy development. You may also sign up to be notified when these products launch.
To address these challenges, LineaBio has introduced the GMP-grade hiPSC lines, Linea 1 and Linea 2, produced under defined, quality-controlled processes. In partnership with º£½ÇÆƽâ°æ Technologies, matched research-grade equivalents are derived from the same source material and qualified to meet or exceed ISSCR standards. Selecting matched starting materials enables smoother advancement through development stages and lowers the likelihood of requiring process redesign at later phases.
Watch this webinar to learn how LineaBio’s GMP-grade manufacturing framework, combined with º£½ÇÆƽâ°æ’s rigorous quality control for matched research-grade cell lines, can support your PSC-derived cell therapy development. You may also sign up to be notified when these products launch.
Publish Date:
January 28, 2026
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to º£½ÇÆƽâ°æ Technologies Canada Inc. and its subsidiaries and affiliates (“º£½ÇÆƽâ°æâ€) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
This site is protected by reCAPTCHA and the Ìý²¹²Ô»åÌýÌý²¹±è±è±ô²â.
This site is protected by reCAPTCHA and the Ìý²¹²Ô»åÌýÌý²¹±è±è±ô²â.
Related Multimedia
-
ISSCR Standards in Action: Advancements in Cell Line Generation and Organoid Innovation
Publish Date: August 01, 2024 -
Differentiation of Human Pluripotent Stem Cells to Immune Cells for Cell Therapy Development
Publish Date: August 04, 2025 -
Scaling-Up hPSC-Derived Cardiomyocytes for Preclinical and Therapeutic Applications
Publish Date: February 21, 2025
Explore Our Products
-
Healthy Control Human iPSC Line, Female, SCTi003-A
Human pluripotent stem cell line, frozen -
cGMP, stabilized feeder-free maintenance medium for human ES and iPS cells -
cGMP, animal origin-free, stabilized, feeder-free maintenance medium for human ES and iPS cells
